Papers/PMID:31870381
Effect of atorvastatin treatment on circulating adiponectin: a meta-analysis of randomized controlled trials.
Lipids in health and disease2019The record
1 finding · 1 compound · 1 endpoint · 1 null
What it reported
How to read these marksEvery finding here is a null result.
What did not
1 finding
atorvastatin — no detected effect on serum adiponectin
ModerateEvidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.FindingNull result“Meta-analysis with a random-effect model showed that atorvastatin did not significantly affect circulating adiponectin as compared with controls (WMD = − 0.27 μg/mL, 95% CI: − 0.89 to 0.35 μg/mL, p = 0.39; Fig. 2a).”
Quoted verbatim from Effect of atorvastatin treatment on circulating adiponectin: a meta-analysis of randomized controlled trials.. - Study
- meta-analysis
- Dose
- 10 to 80 mg/day, 4 to 30 weeks
- Population
- Patients with various conditions (hyperlipidaemia, type 2 diabetes, hypertension, coronary artery disease, rheumatoid arthritis) in ten randomised trials, 14 datasets, oral atorvastatin versus placebo or blank control
Effect -0.27 mean difference, 95% CI -0.89 to 0.35
Effect of atorvastatin treatment on circulating adiponectin: a meta-analysis of randomized controlled trials.2019PMID:31870381Permalink